Holen Sie sich die Stockscreener-App
41.15
6.17%
2.39
Handel nachbörslich:
40.87
-0.28
-0.68%
Scholar Rock Holding Corp Aktie (SRRK) Neueste Nachrichten
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $42.67 Average PT from Brokerages - MarketBeat
What makes Scholar Rock Holding Corporation stock price move sharplyFree AI-Powered Stock Predictions - Newser
How Scholar Rock Holding Corporation stock performs during market volatilityCapital Preservation Investment Ideas - Newser
Why Scholar Rock Holding Corporation stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
Scholar Rock (NASDAQ:SRRK) Trading Up 6.5%What's Next? - MarketBeat
Scholar Rock CSO Mo Qatanani sells $828,898 in shares By Investing.com - Investing.com Nigeria
Scholar Rock CSO Mo Qatanani sells $828,898 in shares - Investing.com Australia
Scholar Rock Q1 2025 slides: apitegromab advances toward FDA approval with priority review - Investing.com Nigeria
Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 3000E Value Index - MarketScreener
Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 20,316 Shares - MarketBeat
Truist reiterates buy rating on Scholar Rock stock amid SMA therapy potential - Investing.com Nigeria
Is Scholar Rock Holding Corp. overvalued or undervalued? - MarketsMojo
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Abbott Laboratories (ABT) - The Globe and Mail
Scholar Rock's Breakthrough SMA Drug Shows Positive Phase 3 Results, FDA Fast-Tracks Review - Stock Titan
Scholar Rock (NASDAQ:SRRK) Trading Down 5.7% – Time to Sell? - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says - MarketScreener
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial - Insider Monkey
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush - MarketBeat
Why Scholar Rock Shares Are Soaring Today - The Globe and Mail
Scholar Rock (NASDAQ:SRRK) Shares Gap UpWhat's Next? - MarketBeat
Transcript : Scholar Rock Holding CorporationSpecial Call - MarketScreener
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Yahoo Finance
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
Scholar Rock stock soars after drug shows promise in preserving lean mass during weight loss - Investing.com Australia
Trading Day Triumph: Scholar Rock Holding Corp (SRRK) Ends at 31.15, a -3.05 Surge/Plunge - DWinneX
Scholar Rock's drug helps Zepbound patients retain more muscle in trial - marketscreener.com
Scholar Rock (SRRK) Surges 14% Following EMBRAZE Trial Results | SRRK Stock News - GuruFocus
Scholar Rock (SRRK) Surges After Promising Weight Loss Trial - GuruFocus
Scholar Rock Reports Positive Results From Phase 2 EMBRAZE Study - Nasdaq
Scholar Rock stock gains on weight loss data (SRRK:NASDAQ) - Seeking Alpha
Scholar Rock (SRRK) Reveals Phase 2 Trial Success of Apitegromab with Tirzepatide | SRRK Stock News - GuruFocus
Scholar Rock's drug helps patients on Zepbound preserve muscle in trial - MarketScreener
Scholar Rock’s apitegromab preserves lean mass during weight loss - Investing.com
Scholar Rock's drug helps preserve lean mass in mid-stage trial - marketscreener.com
Scholar Rock's Breakthrough Drug Shows 55% Better Muscle Preservation in Weight Loss Study - Stock Titan
Scholar Rock’s apitegromab preserves lean mass during weight loss By Investing.com - Investing.com Nigeria
Notable Two Hundred Day Moving Average CrossSRRK - Nasdaq
Scholar Rock Holding Corp Executives Sell Shares to Cover Tax Obligations - TradingView
GAMMA Investing LLC Buys 30,140 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) - MarketBeat
GAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Rhumbline Advisers Purchases 7,491 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Scholar Rock at Goldman Sachs Conference: Strategic Focus on SMA By Investing.com - Investing.com Nigeria
Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Scholar Rock Holding Co. (NASDAQ:SRRK) Stake Increased by California State Teachers Retirement System - MarketBeat
Scholar Rock (NASDAQ:SRRK) Trading Up 5.9%Here's What Happened - MarketBeat
Lifesci Capital Weighs in on Scholar Rock Q2 Earnings - MarketBeat
Scholar Rock (NASDAQ:SRRK) Upgraded at Lifesci Capital - MarketBeat
Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance
Mackenzie Financial Corp Invests $212,000 in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
3.40%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):